Evaxion to present new phase 2 immune data for EVX-01 melanoma vaccine at SITC 2026

Bitget2026/10/02 13:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Evaxion flagged new immune data from its phase 2 EVX-01 personalized cancer vaccine study in advanced melanoma.
Results will be presented at SITC 2026 in November, following a three-year clinical update scheduled for ESMO on Oct. 24, 2026.
The readout is expected to show broader immune effects for EVX-01 with pembrolizumab beyond vaccine-specific responses.
Earlier findings already presented indicated strong, sustained clinical benefit in patients treated with the combination.
Year-three follow-up will also gauge EVX-01 activity as a stand-alone therapy, informing durability and potential positioning beyond anti-PD-1 use.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610020900OMX_____CNEWS_EN_GNW1001275992_en) on October 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Evaxion to present new phase 2 immune data for EVX-01 melanoma vaccine at SITC 2026

You may also like

Crypto prices